N2OFF, Inc. Files 8-K on Shareholder Votes & Financials
Ticker: NXTS · Form: 8-K · Filed: Sep 25, 2025 · CIK: 1789192
Sentiment: neutral
Topics: corporate-action, financial-reporting, name-change
TL;DR
N2OFF (formerly Save Foods) filed an 8-K covering shareholder votes and financials.
AI Summary
N2OFF, Inc. filed an 8-K on September 25, 2025, reporting on matters submitted to a vote of security holders, other events, and financial statements/exhibits. The company, formerly known as Save Foods, Inc., is incorporated in Delaware and has its principal executive offices in Neve Yarak, Israel.
Why It Matters
This filing provides updates on corporate actions and financial reporting for N2OFF, Inc., which could impact investor decisions.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate events and financial information, not indicating immediate operational or financial distress.
Key Players & Entities
- N2OFF, Inc. (company) — Registrant
- Save Foods, Inc. (company) — Former company name
- September 25, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Neve Yarak, Israel (location) — Address of principal executive offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in the excerpt.
What 'Other Events' are being reported by N2OFF, Inc.?
The filing lists 'Other Events' as an item, but the specific nature of these events is not detailed in the provided text.
When did N2OFF, Inc. change its name from Save Foods, Inc.?
The company was formerly known as Save Foods, Inc. and the date of name change was April 10, 2023.
What is the SIC code for N2OFF, Inc.?
The Standard Industrial Classification (SIC) code for N2OFF, Inc. is 2870, which corresponds to AGRICULTURE CHEMICALS.
Where are N2OFF, Inc.'s principal executive offices located?
The principal executive offices of N2OFF, Inc. are located at HaPardes 134 (Meshek Sander) Neve Yarak, Israel, 4994500.
Filing Stats: 990 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2025-09-25 16:30:55
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share NITO The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 55KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 15KB
- 0001493152-25-014952.txt ( ) — 259KB
- nito-20250925.xsd (EX-101.SCH) — 3KB
- nito-20250925_lab.xml (EX-101.LAB) — 33KB
- nito-20250925_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On September 25, 2025, N2OFF, Inc. (the "Company") held a special general meeting of stockholders (the "Special Meeting"). As of the close of business on August 1, 2025, the record date for the Special Meeting, there were 33,356,412 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock") issued and outstanding, each of which was entitled to one vote per share. At the Special Meeting, the holders of 18,575,909 shares of the Common Stock, equivalent to approximately 55.68% of the outstanding shares entitled to vote at the Special Meeting, were represented in person or by proxy at the Special Meeting, constituting a quorum. The matters that were voted upon at the Special Meeting, and the number of votes cast for or against, as well as the number of abstentions and broker non-votes, as to such matters, where applicable, are set forth below. On September 22, the Company effected a one-for-thirty-five (1-for-35) reverse stock split of its common stock. All share amounts set forth below are presented on a pre-split basis. Proposal #1. The Acquisition Proposal . Proposal No. 1 was to approve a proposed acquisition by the Company of all of the share capital of MitoCareX Bio Ltd. , a private company incorporated under the laws of the State of Israel ("MitoCareX"), pursuant to the terms and conditions of the Securities Purchase and Exchange Agreement dated February 25, 2025, as amended on May 18, 2025 and July 23, 2025 (the "Purchase Agreement"), which includes the issuance of shares of the Company's Common Stock that is equal to or in excess of 20% of the Company's outstanding Common Stock before the issuance, in accordance with applicable Nasdaq Listing Rules, and the execution, delivery and performance of the Purchase Agreement and the transactions contemplated thereby. The proposal was approved as follows: For Against Abstain Broker Non-Votes 11,687,364 197,347
01 Other Events
Item 8.01 Other Events. On September 25, 2025, the Company issued a press release announcing that N2OFF's Stockholders Approved a merger with drug discovery company targeting resistant cancers Including pancreatic and non-small cell lung cancer. A copy of the Company's press release is attached hereto as Exhibit 99.1 Item 9.01 Financial Statements and Exhibits Exhibit No. 99.1 Press Release issued September 25, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. N2OFF, Inc. Date: September 25, 2025 By: /s/ Lital Barda Name: Lital Barda Title: Chief Financial Officer